Sarepta Therapeutics (NASDAQ: SRPT) options priced for movement into expected FDA decision

September 14, 2016 6:11 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) is recently up $3.35 to $28.95 in the premarket on hope for a decision on the delayed FDA decision regarding eteplirsen. September call option implied volatility is at 131, September weekly is at 147, October is at 187; compared to its 52-week range of 68 to 399.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment